• About us
• Contact

Advertisement

Organisation › Details

Ferring (Paulsen Foundation) (Group)

Ferring Pharmaceuticals is a privately owned, research-driven, specialty biopharmaceutical group committed to building families and helping people live better lives. We are leaders in reproductive medicine and maternal health, and in areas of gastroenterology and urology. We are at the forefront of innovation in microbiome-based therapeutics and uro-oncology intravesical gene therapy. Ferring was founded in 1950 and employs more than 7,000 people worldwide. The company is headquartered in Saint-Prex, Switzerland, and has operating subsidiaries in more than 50 countries which markets its medicines in over 100 countries. *

 

	Start	1950-01-01 established
	Industry	pharmaceutical
	Person	Paulsen, Frederik (Ferring 201911 Chairman)
	Region	Switzerland_oo
	Country	Switzerland
	Street	50 Ch. de la Vergognausaz
	City	1162 Saint-Prex
	Tel	+41-58-301-0000
		Address record changed: 2020-12-02
Basic data	Employees	G: 5,001 to 10,000 (2024-10-03)
	Currency	EUR
	Annual sales	2,196,468,000 (revenues, total, consolidated (2023) 2023-12-31)
	Profit	118,468,000 (2023-12-31)
	Cash	900,317,000 (2023-12-31)
		* Document for »About Section«: Ferring Pharmaceuticals S.A.. (10/3/24). "Press Release: Ferring Bolsters Global Gene Therapy Supply Chain with European Manufacturing Facility". Saint-Prex.
		Record changed: 2025-03-16

Advertisement

More documents for Ferring (Paulsen Foundation) (Group)

• [1] Ferring Pharmaceuticals S.A.. (10/3/24). "Press Release: Ferring Bolsters Global Gene Therapy Supply Chain with European Manufacturing Facility". Saint-Prex....
• [2] Cyprumed GmbH. (1/24/22). "Press Release: Cyprumed GmbH Enters Agreement with Ferring Pharmaceuticals for Development of Oral Drug Delivery Technology for Patient-Centric non-invasive Peptide Therapeutics". Innsbruck....
• [3] Ipsen S.A.. (12/18/19). "Press Release: Ipsen Announces Departure of David Meek as Chief Executive Officer". Paris....
• [4] Ferring Pharmaceuticals S.A.. (12/18/19). "Press Release: FerGene Appoints David Meek Chief Executive Officer". Cambridge, MA....
• [5] Ferring Pharmaceuticals S.A.. (12/5/19). "Press Release: FerGene Announces Pivotal Phase 3 Study of Nadofaragene Firadenovec Met Its Primary Endpoint". Washington, DC....
• [6] Ferring Pharmaceuticals S.A.. (11/25/19). "Press Release: Ferring and Blackstone Life Sciences Invest over $570 Million USD in Novel Gene Therapy for Bladder Cancer Patients". Saint-Prex & Cambridge, MA....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.